<DOC>
	<DOCNO>NCT01061710</DOCNO>
	<brief_summary>The purpose study collect efficacy safety information subject retreat varenicline ( Champix® ) within 52 week initial treatment appropriate use daily practice participant varenicline Drug Use Investigation protocol A3051109 ( ( NCT # NCT00772941 ) .</brief_summary>
	<brief_title>Varenicline ( Champix® ) Special Investigation ( Regulatory Post Marketing Commitment Plan )</brief_title>
	<detailed_description>The subject retreat varenicline within 52 week , subject enrol varenicline Drug Use Investigation protocol A3051109 .</detailed_description>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Male Female subject intend quit tobacco use prescribed varenicline ( Champix® ) Physicians Subjects prescribe varenicline ( Champix® ) second time within 52 week initial treatment . Nonparticipants varenicline ( Champix® ) Drug use Investigation protocol A3051109 .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>Smoking</keyword>
	<keyword>smoke cessation</keyword>
	<keyword>Japanese</keyword>
	<keyword>varenicline</keyword>
	<keyword>retreatment</keyword>
	<keyword>Regulatory Post Marketing Commitment Plan</keyword>
</DOC>